Search for: "Oncology Therapeutics Corp."
Results 1 - 9
of 9
Sorted by Relevance
|
Sort by Date
25 Jan 2019, 12:00 am
The first being Bristol Myers Squibb Co’s (BMY) acquisition of Celgene Corp. [read post]
16 Nov 2010, 6:13 pm
WaferGen Biosystems Inc and Generex Biotechnology Corp have received grants from the IRS and the Department of Health and Human Services under the Qualifying Therapeutic Discovery Project program established under Section 48D of the Internal Revenue Code. [read post]
31 Mar 2017, 6:56 am
Argos Therapeutics, Inc., et al., No. 1:17-cv-00216 (M.D.N.C. [read post]
31 Mar 2017, 6:56 am
Argos Therapeutics, Inc., et al., No. 1:17-cv-00216 (M.D.N.C. [read post]
17 May 2016, 4:24 am
Healthcare companies in its current portfolio include AMD Holdings, a healthcare supply chain solutions provider; Kastle Therapeutics, a biopharmaceutical company focused on acquiring, developing and commercializing specialty pharmaceuticals; Summit Behavioral Healthcare, a provider of addiction treatment and behavioral health services; and Top Rx, a distributor of generic and branded pharmaceuticals, vitamins, OTC healthcare products and pharmacy supplies. [read post]
2 Nov 2016, 4:57 am
Companies in its current portfolio include AccentCare, a full-service provider of home healthcare services, and Vantage Oncology, an owner and operator of outpatient radiation oncology centers in more than a dozen states. [read post]
17 Aug 2009, 10:44 am
(Whitman, MA; Ann Calitri, President) Ag Therapeutics Incorporated (Boston, MA; Anthony Guarino, President) Ag Transportation, Inc. [read post]
26 Dec 2017, 7:08 pm
In another important case, drug manufacturer Mylan Inc. paid approximately $465 million to resolve allegations that it underpaid rebates owed under the Medicaid Drug Rebate Program by erroneously classifying its patented, brand name drug EpiPen – which has no therapeutic equivalents or generic competition – as a generic drug to avoid its obligation to pay higher rebates. [read post]
16 Feb 2021, 2:23 pm
M&T Bank Corp., 962 F.3d 701, 717 (3d Cir. 2020). [read post]
